Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 1, 2001 - Issue 2
Submit an article Journal homepage
273
Views
1
CrossRef citations to date
0
Altmetric
Editorial

Estrogen therapy in postmenopausal women with Parkinson’s disease

Kin-Lun Tsang Division of Neurology, University Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, P.R. China. [email protected]
&
Shu-Leong Ho Division of Neurology, University Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, P.R. China. [email protected]
Pages 135-137 | Published online: 10 Jan 2014

References

  • Xie T, Ho SL, Ramsden D. Characterization and implications of estrogenic downregulation of human catechol-O-methyltransferase gene transcription. Mal Phannacol 56(1), 31–38 (1999).
  • Parvez S, Parvez SH, Youdim MB. Variation in activity of monoamine metabolizing enzymes in rat liver during pregnancy. BE J. Phannacol 53,241–246 (1975).
  • Parvez S, Ismahan G, Raza BA, Youdim MB. Activity of catechol-O-methyltransferase in brain regions and adrenal gland during the estrus cycle. Neural Tiansm. 42,305–312 (1978).
  • Pasqualini C, Olivier V, Guibert B, Frain O, Leviel V. Acute stimulatory effect of estradiol on striatal dopamine synthesis. Neurochem. 65,1651–1657 (1995).
  • Morissette M, Biron D, Di Paolo T Effect of estradiol and progesterone on rat striatal dopamine uptake sites. Brain Res. Bull 25(3), 419–422 (1990).
  • Morissette M, Di Paolo T Effect of chronic estradiol and progesterone treatments of ovariectomized rats on brain dopamine uptake sites. Neurochem. 60(5), 1876–1883 (1993).
  • Hruska RE, Nowak MW. Estrogen treatment increases the density of D1 dopamine receptors in the rat striatum. Brain Res. 442,349–350 (1988).
  • Hruska RE, Silbergeld EK. Increased dopamine receptor sensitivity after estrogen treatment using the rat rotation model. Science 208,1466–1468 (1980).
  • Blanchet PJ, Fang J, Hyland K, Arnold LA, Mouradian MM, Chase TN. Short-term effects of high-dose 1713-estradiol in postmenopausal PD patients: A cross-over study. Neurology53,91–95 (1999).
  • Sawada H, Ibi M, Kihara T, Urushitani M, Akaike A, Shimohama S. Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death. I Neurosci. Res. 54,707–719 (1998).
  • Behl C, Widmann M, Trapp T, Holsboer 17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem. Biophys. Res. Commun. 216(2), 473–482 (1995).
  • Singer CA, Rogers KL, Strickland TM, Dorsa DM. Estrogen protects primary cortical neurons from glutamate toxicity. Neurosd Lett. 212(1), 13–16 (1996).
  • Dluzen D. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res. 767,340–344 (1997).
  • Dluzen DE, McDermott JL, Liu B. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxical 7eratol 18(5), 603–606 (1996).
  • Bedard P, Langelier P, Villeneuve A. Estrogens and extrapyramidal system. Lancet ii, 1367–1368 (1977).
  • Koller WC, Barr A, Biary N. Estrogen treatment of dyskinetic disorders. Neurology 32,547–549 (1982).
  • Lyons KE, Hubble JP, Troster Al, Pahwa R, Koller WC. Gender differences in Parkinson's disease. Clin. Neuropharmacol 21(2), 118–121 (1998).
  • Quinn NP, Marsden CD. Menstrual-related fluctuations in Parkinson's disease. Mov. Disad 1,85–87 (1986).
  • Sandyk R. Estrogens and the pathophysiology of Parkinson's disease.Intern. Neurosd 45,119–122 (1989).
  • Benedetti MD, Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Postmenopausal estrogen replacement therapy and Parkinson's disease: a population based study in Olmstead Country, Minnesota. Mov. Disarl 13\(Suppl. 2), 51 (1998).
  • Saunders-Pullman RJ, Gordon-Elliott J, Parides M, Palm S, Saunders HR, Bressman S. The effect of hormone replacement therapy on early Parkinson's disease. Neumlogy52, 1417–1421 (1999).
  • Tanner CM, Hubble JP, Chan Piu. Epidemiology and genetics of Parkinson's disease. In: Movement Disorders: Neurologic principles and practice. (Eds.), Watts RL, Koller WC, McGraw-Hill, New York, USA. 137–152 (1997).
  • Diamond SG, Markham CH, Hoehn MM, Mcdowell PH, Muenter MD. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology 40,763–766 (1990).
  • Strijks E, Kremer JA, Horstink MW. Effects of female sex steroids on Parkinson's disease in postmenopausal women. Clin. Neumpharmacol 22,93–97 (1999).
  • Tsang KL, Ho SL, Lo SK. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology54 (12), 2292–2298 (2000).
  • Grandbois M, Morissette M, Callier S, Di Paolo T Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. Neural-Tort 11(2), 343–346 (2000).
  • Yaffe K, Krueger K, Sarkar S, eta]. Cognitive function in postmenopausal women treated with raloxifene. N Eng J. Med. 344(16), 1207–1213 (2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.